Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-04-11
2009-02-03
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C435S320100, C435S325000, C435S455000
Reexamination Certificate
active
07485627
ABSTRACT:
The invention provides a method for ameliorating gastrointestinal inflammation, particularly chronic gastrointestinal inflammation such as inflammatory bowel disease (IBD), in a subject. In one embodiment, the method comprises administering an immunomodulatory nucleic acid to a subject suffering from or susceptible to gastrointestinal inflammation.
REFERENCES:
patent: 5716615 (1998-02-01), Cavaliere Vesely et al.
patent: 5736524 (1998-04-01), Content et al.
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6214806 (2001-04-01), Krieg et al.
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6228371 (2001-05-01), Nano et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: WO 98/18810 (1998-05-01), None
patent: WO 00/01851 (2000-01-01), None
patent: WO 00/01851 (2000-01-01), None
patent: WO 01/22972 (2001-04-01), None
patent: WO 01/22990 (2001-04-01), None
Obermeier et al. Clin Exp Immunol. Nov. 2003 134:217-224.
Baert et al. Gastroenterology 1999;116:22-28.
Shimosato et al. Animal Science Journal (2004) 75, 377-382.
Obermeier et al. Clin Exp Immunol 2003 134:217-224.
Goldberg et al 2000 Immunology Letters.73:13-18.
Yamada et al 2002 Journal of Immunology p. 5594.
Krieg, “Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides” Biochimica et Biophysica Acta. Gene Structure and Expression, Elsevier Amsterdam, NL, vol. 1489, No. 1, Dec. 10, 1999, pp. 107-116.
Krieg “The role of CpG motifs in innate immunity” Current Opinion in Immunology, Current Biology, Ltd. vol. 12, No. 1, Feb. 1, 2000, pp. 35-43.
Selby et al. (2000) “Pathogenesis and therapeutic aspects of Crohn's disease.”Veterinary Microbiology, vol. 77:505-511.
Asseman et al. (1999) “An Essential Role for Interleukin 10 in the Function of Regulatory T Cells that Inhibit Intestinal Inflammation.”J. Exp. Med., vol. 190(7):995-1003.
Bamford (1999) “Chronic Gastrointestinal Inflammation.”FEMS Immunology and Medical Microbiology, vol. 24:161-168.
Bhan et al. (1999) “Colitis in Transgenic and Knockout Animals as Models of Human Inflammatory Bowel Disease.”Immunological Reviews, vol. 169:195-207.
Blumberg et al. (1999) “Animal models of mucosal inflammation and their relation to human inflammatory bowel disease.”Current Opinions in Immunology, vol. 11:648-656.
Blumberg et al. (2001) “Prospects for research in Inflammatory Bowel Disease.”JAMA, vol. 285(5):643-647.
Dieleman et al. (1998) “Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines.”Clin. Exp. Immunol., vol. 114:385-391.
Dohi et al. (1999) “Hapten-induced Colitis is Associated with Colonic Patch Hypertrophy and T Helper Cell 2-Type Responses.”J. Exp. Med., vol. 189(8):1169-1179.
Hyams (2000) “Coricosteroids in the treatment of gastrointestinal disease.”Current Opinion in Pediatrics, vol. 12:451-455.
Iijima et al. (1999) “Alteration of Interleukin 4 Production Results in the Inhibition of T Helper Type 2 Cell-dominated Inflammatory Bowel Disease in T Cell Receptor α Chain-deficient Mice.”J. Exp. Med., vol. 190(5):607-615.
MacDonald (1997) “Cytokine gene delted mice in the study of gastrointestinal inflammation.”Eur. J. Gastroenterol.&Hepatol., vol. 9:1051-1055.
Mayer et al. (2000) Current concept of IBD: Etiology and Pathogenesis. In “Inflammatory Bowel Disease.” 5thEdition, Kirsner JB editor, W.B. Saunders Company, pp. 280-296.
Mikula (1999) “Anti-TNFα: New Therapy for Crohn's Disease.”Gastroenterol Nurs., vol. 22(6):245-8.
Nagura et al. (2001) “The Immuno-Inflammatory Mechanism for Tissue Injury in Inflammatory Bowel Disease and Helicobacter pylori-Infected Chronic Active Gastritis.”Digesion, vol. 63(1):12-21.
Neurath et al. (1997) “Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice.”Eur. J. Immunol., vol. 27:1743-1750.
Neurath et al. (2000) “TNBS-Colitis.”Int. Rev. Immunol., vol. 19:51-6.
Nishimura et al. (1999) “Distinct Role of Antigen-specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in vivo.”J. Exp. Med., vol. 190(5):617-627.
Papadakis et al. (2000) “Role of Cytokines in the Pathogenesis of Inflammatory Bowel Disease.”Annu. Rev. Med., vol. 51:289-298.
Podolsky (1999) “Mucosal Immunity and Inflammation V. Innate mechanisms of mucosal defense and repair: the best offense is a good defense.”Am. J. Physiol., vol. 277:G495-499.
Pohl et al. (2000) “Chronic Inflammatory Bowel Disease and Cancer.”Hepato-Gastroenterology, vol. 47:57-70.
Roman et al. (1997) “Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.”Nature Medicine, vol. 3(8):849-854.
Sartor (1997) “Pathogenesis and Immune Mechanisms of Chronic Inflammatory Bowel Diseases.”The Amer. Journal of Gastroenterology, vol. 92(12):5S-11S.
Schappi et al. (2001) “Colitis in chronic granulomatous disease.”Arch. Disc. Child., vol. 84:147-151.
Walker-Smith (2000) “Chronic inflammatory bowel disease in children: a complex problem in management.”Postgrad Med. J.,vol. 76(898):469-472.
Janeway “Basic Concepts in Immunology” 5THEdition, c 2000,Immuno Biology.
Janeway et al., “Manipulation of the Immune Response” 4THEdition (1999),Immuno Biology, pp. 536-539.
Nagler-Anderson et al., “Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen”, Prac. Natl. Acad. Sci. (1986), 83:7743-7446.
Desvignes et al., “Oral Administration of Hapten Inhibits In Vivo Induction of Specific Cytotoxic CD8 T Cells Mediating tissue Inflammation: A Role for Regulatory CD4 T Cells” The Journal of Immunology (2000) 2515-2522.
Raghavan et al., “Orally Administered CpG Oligodeooxynucleotide Induces Production of CXC and CC Chemokines in the Gastric Mucosa and Suppresses Bacterial Colonization in a Mouse Model of Helicobacter Pylori Infection” Infection and Immunity (2003) 71:7014-7022.
Kuolee et al., “Mouse Model of Oral Infection with Virulent Type AFrancisella tularensis” Infection and Immunity (2007) 75:1651-1660.
Rachmilewitz Daniel
Raz Eyal
Archie Nina A
Borden Paula A.
Bozicevic Field & Francis LLP
Navarro Mark
Tel Aviv Sourasky Medical Center
LandOfFree
Method for treating inflammatory bowel disease and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating inflammatory bowel disease and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating inflammatory bowel disease and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4100369